Articles related to BLOOD CANCERS

A retrospective cohort of 146 adult patients with T-cell ALL treated with a pediatric-inspired regimen at a single center achieved 3-year overall survival of 73% and leukemia-free survival of 77%, with age over 60 emerging as the primary adverse prognostic factor and early T-cell precursor phenotype showing no independent survival impact.

Tafasitamab plus lenalidomide added to R-CHOP reduced the risk of progression or death by 25% compared with R-CHOP alone in previously untreated high-risk DLBCL and HGBL in a 899-patient phase 3 trial, with overall survival data not yet mature.

Leukemia progression depends on where cells are affected in the maturation process, determining treatment urgency and functional capacity of abnormal blood cells.

Despite poor prognosis at treatment initiation, extended follow-up reveals sustained remissions suggesting curative potential in heavily pretreated CLL patients receiving CD19-directed cellular immunotherapy.

Five-year survival rates for chronic lymphocytic leukemia show promising outcomes even in elderly patients, with 77% survival in those 75 and older.

The 2024 ASCO Annual Meeting reveals critical updates on lung and blood cancers, including promising phase 3 trial results and the innovative use of AI to reengage marginalized patients in cancer care.